World News | Carolyn Y. Johnson, Brady Dennis, The Washington Post | Wednesday December 2, 2015
Gilead Sciences executives were acutely aware in 2013 that their plan to charge an exorbitantly high price for a powerful new hepatitis C drug would spark public outrage, but they pursued the profit-driven strategy anyway, according to a Senate Finance Committee investigation report released Tuesday.
www.ndtv.com